Artiva Biotherapeutics, Inc. (ARTV)

Artiva Biotherapeutics was planning to go public, but the IPO has been withdrawn.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Data will show when the stock starts trading.
Market Cap n/a
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About ARTV

Artiva Biotherapeutics' mission is to deliver highly effective, off-the-shelf, allogeneic, natural killer (NK) cell-based therapies that are safe and accessible to cancer patients. Our established manufacturing-first approach has enabled us to produce, store and ship our product candidates and make them accessible like traditional protein biologic therapies. Our lead product candidate, AB-101, is an off-the-shelf NK cell therapy that is currently being studied in a Phase 1/2 trial with rituximab in patients with non-Hodgkin’s lymphoma (NHL). ... [Read more]

Industry Biological Products
Founded 2019
CEO Fred Aslan, M.D.
Employees 25
Stock Exchange NASDAQ
Ticker Symbol ARTV
Full Company Profile


There is no news available yet.